Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

CU Cancer Center’s Paul Bunn, Jr., MD, FASCO, Earns ASCO David A. Karnofsky Memorial Award
  • USA - English


News provided by

University of Colorado Cancer Center

Jun 02, 2016, 10:00 ET

Share this article

Share toX

Share this article

Share toX

Paul Bunn, Jr., MD, FASCO
Paul Bunn, Jr., MD, FASCO

I view this award as an honor but also as an indication of progress in the field of lung cancer.

Post this

Aurora, Colo. (PRWEB) June 02, 2016 -- Paul Bunn, Jr., MD, FASCO, distinguished professor at the University of Colorado Cancer Center and James Dudley Professor of Lung Cancer Research at the University of Colorado School of Medicine has been named the 2016 David A. Karnofsky Memorial Award and Lecture recipient, a prestigious award presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting. Dr. Bunn’s distinguished career in lung cancer research includes more than 320 peer-reviewed articles, 200 reviews and 90 book chapters. He has been principal investigator on many national and local clinical trials and is the principal investigator on the NCI’s CU Cancer Center SPORE grant in lung cancer, designed to speed the progress of new treatments from basic research to clinical use. Dr. Bunn served as ASCO President from 2002 to2003, as president and CEO of the International Association for the Study of Lung Cancer, chairman of the FDA Oncology Drug Advisory Committee, and is the founding director of the CU Cancer Center.

“I view this award as an honor but also as an indication of progress in the field of lung cancer,” Bunn says. “In the last decade, molecular therapies and immunotherapies have improved outcomes for lung cancer patients considerably. New screening protocols and methods have reduced mortality. And getting people to stop smoking has made a huge impact. I view this award as a tribute to those people who made these advances in prevention, early detection, pathology, staging and treatment.”

The award is named after David A. Karnofsky, researcher and oncologist at Harvard University and then Memorial Sloan Kettering Cancer Center. Karnofsky was instrumental in the development of the first chemotherapies and then described what became known as the Karnofsky Performance Status Scale, which quantified a patient’s ability to withstand chemotherapy and became a standard tool in choosing cancer treatments. Karnofsky died of lung cancer in 1969.

Bunn’s career has focused on creating insights from lung cancer biology to inform the development of targeted treatments. This has included pioneering studies of lung cancer cells exploring their genetic and genomic vulnerabilities. Understanding these vulnerabilities has driven a paradigm shift in lung cancer treatment, from exclusively chemotherapy/radiation to targeted treatments that exploit the specific genetic changes that make a cancer unique.

“For example, understanding that some lung cancers have activating mutations in the epidermal growth factor receptor (EGFR) led to new oral tyrosine kinase inhibitors (TKIs) blocking EGFR signaling,” Bunn says. “Subsequently, investigators found many more activating genetic alterations including ALK, ROS1, BRAF, RET, NTRK and others that have also led to new oral TKIs and improved outcomes.”

Bunn describes the rapid translation of these basic discoveries to FDA-approved therapies and diagnostics that have improved survival and quality of life for lung cancer patients. However, due to the inability to produce complete regressions and the universal development of resistance, when used alone these TKI therapies do not cure advanced lung cancers. Now the challenge is to increase the effectiveness of these treatments, leading to, as Bunn says, “less side effects, more efficacy and longer duration.”

According to Bunn, the answer will again be found in the biology of the disease, both in new understanding of mechanisms that allow lung tumors to persist when challenged by these medicines and in the development of rational combinations of these medicines to combat cancers synergistically.

In addition to TKIs, Bunn sees great promise in immunotherapies designed to recruit the body’s immune system to attack tumor tissue and points out that new strategies and refinements of existing strategies are aiding efforts to prevent and diagnose the disease.

However, while basic biology may be the engine that allows the development of new cancer therapies, Bunn does not see understanding alone as the field’s endpoint. “A scientist can sit at a bench all day and nothing’s going to happen unless you also have a doctor and a patient,” Bunn says. “Advances in cancer treatment require the scientist, the clinician, the patient and well-designed clinical trials.”

Bunn extends these needs to include a careful regulatory environment that balances the needs of safety and speed, and also to funding for research, testing and care.

“The reality is that the investment in research has worked. Understanding the biological principles has resulted in treatments that help patients,” he says. Bunn states that he is extremely grateful for the many fruitful collaborations with many outstanding CU basic scientists, pathologists, pulmonologists, medical and radiation oncologists, thoracic surgeons, radiologists, statisticians, and bioinformaticians. These collaborations have made CU a leader in the rapid advances in lung cancer worldwide.

Bunn’s career represents the branch of cancer medicine that has chosen to prioritize the science of the disease. Now the David A. Karnofsy Memorial Award and Lecture recognizes the impact of this approach on patients’ lives.

Garth Sundem, University of Colorado Cancer Center, http://www.coloradocancerblogs.org, +1 (805) 559-2023, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.